This report is an updated version of the report published on 16 September 2026 at 10:39 AM AEST.

1.1: Company Overview: BlinkLab Limited (ASX:BB1) is developing a smartphone-based diagnostic platform for autism assessment. Its flagship product, BlinkLab Dx1, uses smartphones, artificial intelligence, and machine learning to capture objective reflex-based measures for clinicians. The company is supported by expertise across digital healthcare, computer vision, AI, autism research, and brain development. Kalkine’s Healthcare Report covers the Investment Highlights, Management Insights, Key Financial Metrics, Risks, Technical Analysis along with the Valuation, Target Price and Recommendation on the stock.

Past performance is not a reliable indicator of future performance.